Bringing together Bristol Myers Squibb and
Celgene on one clinical trial management system, company goes live
with Vault CTMS in record speed
Modernization streamlines trial management to
speed medicines to patients
PLEASANTON, Calif., April 21,
2022 /PRNewswire/ -- Veeva Systems today
announced that Bristol Myers Squibb has implemented Veeva Vault
CTMS globally to drive end-to-end trial management. The new CTMS
replaced a heritage Celgene CTMS and a heritage Bristol Myers
Squibb CTMS and is tightly integrated with Veeva's eTMF and Study
Startup applications. The total implementation time was less than
20 months.
By launching Veeva's industry-leading trial management and
monitoring solution companywide, Bristol Myers Squibb established
unified, agile, and simple trial processes aimed at making clinical
trials faster and more efficient.
"We're thrilled to expand on our longstanding partnership with
Veeva across R&D," said Greg
Meyers, chief digital and technology officer at Bristol
Myers Squibb. "Veeva's continued commitment to customer success and
product innovation helps us accelerate the development and delivery
of medicines to patients globally."
"Bristol Myers Squibb is one of our most agile and
forward-thinking partners," said Veeva CEO Peter Gassner. "The merger of Bristol Myers
Squibb and Celgene was the largest IT integration project in the
history of pharma and to have completed a single CTMS
implementation in twenty months is truly remarkable. We are very
proud to achieve this milestone together."
"Veeva Vault CTMS is enabling customers with advanced
capabilities that can simplify trial execution at scale," said
Henry Galio, vice president, Veeva
Vault CTMS. "Thank you to the Bristol Myers Squibb team for your
incredible partnership on this very important and complex CTMS
implementation."
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
pharmaceutical companies to emerging biotechs. As a Public Benefit
Corporation, Veeva is committed to balancing the interests of all
stakeholders, including customers, employees, shareholders, and the
industries it serves. For more information,
visit veeva.com.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and services
and the expected results or benefits from use of our products and
services. Such statements are based on our current expectations.
Actual results could differ materially from those provided in this
release and we have no obligation to update such statements. There
are numerous risks that have the potential to negatively impact our
results, including the risks and uncertainties disclosed in our
filing on Form 10-K for the period ended January 31, 2022, which you can
find here (a summary of risks which may impact our
business can be found on pages 13 and 14), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/veeva-vault-ctms-launched-at-bristol-myers-squibb-to-simplify-clinical-trial-processes-globally-301529881.html
SOURCE Veeva Systems